Belgia - engleză - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - bicalutamide 50 mg - film-coated tablet - 50 mg - bicalutamide 50 mg - bicalutamide

Belgia - engleză - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - bicalutamide 150 mg - film-coated tablet - 150 mg - bicalutamide 150 mg - bicalutamide

Belgia - engleză - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - bicalutamide 150 mg - film-coated tablet - 150 mg - bicalutamide 150 mg - bicalutamide

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - bicalutamide (unii: a0z3nau9dp) (bicalutamide - unii:a0z3nau9dp) - bicalutamide 50 mg - bicalutamide tablets, usp 50 mg daily are indicated for use in combination therapy with a luteinizing hormone-releasing hormone (lhrh) analog for the treatment of stage d2 metastatic carcinoma of the prostate. bicalutamide tablets, usp 150 mg daily are not approved for use alone or with other treatments [see clinical studies (14.2)]. bicalutamide is contraindicated in: - hypersensitivity bicalutamide is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet’s components. hypersensitivity reactions including angioneurotic edema and urticaria have been reported. - women bicalutamide has no indication for women, and should not be used in this population. - pregnancy bicalutamide can cause fetal harm when administered to a pregnant woman [see use in specific populations (8.1)]. risk summary bicalutamide is contraindicated for use in pregnant women because it can cause fetal harm. bicalutamide is not indicated for use in females. there are no human data on t

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

bryant ranch prepack - bicalutamide (unii: a0z3nau9dp) (bicalutamide - unii:a0z3nau9dp) - bicalutamide 50 mg - bicalutamide tablets 50 mg daily are indicated for use in combination therapy with a luteinizing hormone-releasing hormone (lhrh) analog for the treatment of stage d2 metastatic carcinoma of the prostate. bicalutamide tablets 150 mg daily are not approved for use alone or with other treatments [see clinical studies (14.2) ]. bicalutamide tablets are contraindicated in: - hypersensitivity bicalutamide tablets are contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet’s components. hypersensitivity reactions including angioneurotic edema and urticaria have been reported. - women bicalutamide tablets have no indication for women, and should not be used in this population. - pregnancy bicalutamide tablets can cause fetal harm when administered to a pregnant woman [see use in specific populations (8.1) ]. risk summary bicalutamide is contraindicated for use in pregnant women because it can cause fetal harm. bicalutamide is not indicated for use in f

Australia - engleză - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - bicalutamide, quantity: 50 mg - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; sodium starch glycollate type a; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - treatment of advanced prostate cancer in combination with lhrh agonist therapy.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - bicalutamide, quantity: 50 mg - tablet, film coated - excipient ingredients: povidone; lactose monohydrate; magnesium stearate; sodium starch glycollate type a; titanium dioxide; hypromellose; macrogol 400 - treatment of advanced prostate cancer in combination with lhrh agonist therapy.

Malta - engleză - Medicines Authority

accord healthcare limited - bicalutamide - film-coated tablet - bicalutamide 50 mg - endocrine therapy

Australia - engleză - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - bicalutamide, quantity: 50 mg - tablet, film coated - excipient ingredients: macrogol 400; lactose monohydrate; povidone; titanium dioxide; hypromellose; magnesium stearate; sodium starch glycollate type a - treatment of advanced prostate cancer in combination with lhrh agonist therapy. prevention of disease flare associated with the use of lhrh agonists.

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

lexon (uk) ltd - bicalutamide - film-coated tablet - 50 milligram(s) - anti-androgens; bicalutamide